Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats.
Chronic hypoxia induces lung vascular remodeling, which results in pulmonary hypertension. We hypothesized that a previously found increase in collagenolytic activity of matrix metalloproteinases during hypoxia promotes pulmonary vascular remodeling and hypertension. To test this hypothesis, we exposed rats to hypoxia (fraction of inspired oxygen = 0.1, 3 wk) and treated them with a metalloproteinase inhibitor, Batimastat (30 mg/kg body wt, daily ip injection). Hypoxia-induced increases in concentration of collagen breakdown products and in collagenolytic activity in pulmonary vessels were inhibited by Batimastat, attesting to the effectiveness of Batimastat administration. Batimastat markedly reduced hypoxic pulmonary hypertension: pulmonary arterial blood pressure was 32 +/- 3 mmHg in hypoxic controls, 24 +/- 1 mmHg in Batimastat-treated hypoxic rats, and 16 +/- 1 mmHg in normoxic controls. Right ventricular hypertrophy and muscularization of peripheral lung vessels were also diminished. Batimastat had no influence on systemic arterial pressure or cardiac output and was without any effect in rats kept in normoxia. We conclude that stimulation of collagenolytic activity in chronic hypoxia is a substantial causative factor in the pathogenesis of pulmonary vascular remodeling and hypertension.
Herget
Jan
J
Department of Physiology, Charles Univ. Second Medical School, Plzenská 130/221, 15000 Praha 5, Czech Republic. jan.herget@lfmotol.cuni.cz
Novotna
Jana
J
Bibova
Jana
J
Povysilova
Viera
V
Vankova
Marie
M
Hampl
Vaclav
V
D000818:Animals; D002908:Chronic Disease; D003094:Collagen / Q000378:metabolism; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000378:metabolism; D017380:Hypertrophy, Right Ventricular / Q000188:drug therapy / Q000378:metabolism; D000860:Hypoxia / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D011652:Pulmonary Circulation; D051381:Rats; D017208:Rats, Wistar; D013047:Specific Pathogen-Free Organisms; D013876:Thiophenes / Q000494:pharmacology*
D011480:Protease Inhibitors; D013876:Thiophenes; D010649:Phenylalanine; D003094:Collagen; C080985:batimastat; D008666:Metalloendopeptidases